METRONIDAZOLE by Fosun Pharma is clinical pharmacology absorption disposition of metronidazole in the body is similar for both oral and intravenous dosage forms. Approved for the treatment of asymptomatic t, the treatment of acute intestinal amebiasis (amebic dysentery), amebic liver abscess and 1 more indications. First approved in 1982.
Drug data last refreshed 21h ago · AI intelligence enriched Yesterday
Metronidazole is a nitroimidazole small-molecule antibiotic effective against anaerobic bacteria and protozoan parasites. It is indicated for treatment of asymptomatic trichomoniasis, acute intestinal amebiasis, amebic liver abscess, and serious infections caused by susceptible anaerobic bacteria. The drug works through reduction of its nitro group in anaerobic organisms, disrupting DNA and inhibiting nucleic acid synthesis.
As loss of exclusivity approaches, brand teams face significant generic erosion; focus shifts to cost management and niche indications rather than market expansion.
CLINICAL PHARMACOLOGY Absorption Disposition of metronidazole in the body is similar for both oral and intravenous dosage forms. Following oral administration, metronidazole is well absorbed, with peak plasma concentrations occurring between one and two hours after administration. Plasma…
Worked on METRONIDAZOLE at Fosun Pharma? Share your interview experience or compensation data (+7 days Pro)
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Chlorhexidine and/or Metronidazole Plus FB301 Pre-treatment Trial
A Single-center, Open-label, Study Evaluating Safety and Pharmacokinetics of Single Doses of Zidebactam-Cefepime and Metronidazole Alone or in Combination.
Effectivity and Safety of Metronidazole 1% Cream in Rosacea Therapy
Personalized AZithromycin/metronidAZole Therapy in Pediatric Crohn's Disease (CD)
Ceftolozane/Tazobactam (MK-7625A) Plus Metronidazole Versus Meropenem for Participants With Complicated Intra-abdominal Infection (MK-7625A-015)
Working on metronidazole offers limited growth opportunity given LOE-approaching status and mature market; career value centers on operational excellence, cost containment, and preserving market share against generics. Ideal for professionals seeking stable, low-innovation roles focused on execution and supply reliability.